Google
Apple
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 589.25 USD | +0.19% | -0.44% | +61.07% | |
| 12-06 | Berenberg: Novo Nordisk Faces Challenging Momentum Picture as Rivals Bite into Obesity Market | MT |
| 12-05 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
| Sales 2023 * | 33.6B 2,673B | Sales 2024 * | 38.84B 3,090B | Capitalization | 530B 42,158B |
|---|---|---|---|---|---|
| Net income 2023 * | 5.29B 421B | Net income 2024 * | 10.69B 850B | EV / Sales 2023 * | 16,2x |
| Net Debt 2023 * | 14.19B 1,129B | Net Debt 2024 * | 11.73B 933B | EV / Sales 2024 * | 13,9x |
| P/E ratio 2023 * | 98,9x | P/E ratio 2024 * | 48,3x | Employees | 39,000 |
| Yield 2023 * | 0,74% | Yield 2024 * | 0,87% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.19% | ||
| 1 week | -0.44% | ||
| Current month | -0.30% | ||
| 1 month | -1.00% | ||
| 3 months | +5.23% | ||
| 6 months | +32.99% | ||
| Current year | +61.07% |
1 week
574.33
601.97
1 month
574.33625.87
Current year
302.14629.97
1 year
302.14629.97
3 years
146.91629.97
5 years
101.36629.97
10 years
48.88629.97
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 55 | 1995 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 50 | 2013 |
Alonzo Weems
CMP | Compliance Officer | - | 1996 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 62 | 2021 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 2009 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 2004 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 26.31% | 475 M€ | -4.32% | - | |
| 14.50% | 4 M€ | +17.27% | - | |
| 10.26% | 16 M€ | 0.00% | - | |
| 10.20% | 212 M€ | +7.52% | ||
| 8.98% | 2,705 M€ | -2.75% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/12/23 | 589.25 | +0.19% | 2,093,105 |
| 05/12/23 | 588.15 | +0.42% | 2,157,343 |
| 04/12/23 | 585.68 | +0.28% | 2,577,122 |
| 01/12/23 | 584.04 | -1.18% | 3,638,565 |
| 30/11/23 | 591.04 | -0.14% | 5,658,350 |
Delayed Quote Nyse, December 06, 2023 at 09:00 pm
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (46.6%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (20.3%);
- immunology diseases (11.8%);
- neurology (6.7%): primarily drugs used in treating depression and schizophrenia;
- other (14.6%).
Net sales are distributed geographically as follows: the United States (59.4%), Europe (16.9%), Japan (8.3%), China (5.9%) and other (9.5%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
589.25USD
Average target price
619.14USD
Spread / Average Target
+5.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +61.07% | 530 B $ | |
| +44.35% | 438 B $ | |
| -11.34% | 377 B $ | |
| -4.79% | 268 B $ | |
| -9.42% | 258 B $ | |
| +0.98% | 200 B $ | |
| -9.65% | 198 B $ | |
| -43.81% | 163 B $ | |
| +2.55% | 144 B $ | |
| -4.20% | 117 B $ |
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition